Organization: Health Canada
Year: 2024
Month: August
Request Number: A-2024-000122
Request Summary: The name of the company (sponsor) who submitted the Second Semaglutide Abbreviated New Drug Submission (ANDS); and the year and month in which the Second Semaglutide ANDS was accepted for review. Per Health Canada’s Notice: Expansion of the Generic Submissions Under Review List (February 23, 2024).
Disposition: Disclosed in part
Number of pages: 2